Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.

Five-year results of the ABSORB III trial suggest that, while target lesion failure and scaffold thrombosis have remained apparent in patients implanted with bioresorbable vascular scaffolds, the poor outcomes associated with BVS seemed to subside after three years, when the stents had completely dissolved.

The transcarotid approach to TAVR is becoming more common, according to research presented at TVT.19.

Sometimes a move in the right direction starts with a good hard look in the rearview mirror, then breaking it off to start anew with greater wisdom.

Medical directors of cardiac catheterization and EP labs receive three to four times the amount of money from pharmaceutical companies and device manufacturers as other interventional cardiologists in the same zip code, according to a JAMA Internal Medicine study.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.

Corindus Vascular Robotics’ CorPath GRX system—the world’s only FDA-approved and CE-marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention—was used in the first-ever live transmission of a robotic PCI in Europe during this year's EuroPCR congress.